Our Mission

The National Hemophilia Foundation (NHF) Central Ohio Chapter is dedicated to finding cures for inheritable blood disorders and addressing and preventing the complications of these disorders through research, education, and advocacy enabling people and families to thrive.

News & Announcements

FOR IMMEDIATE RELEASE

MEDIA CONTACT:

Ilana Ostrin

212-328-3769
iostrin@hemophilia.org

Meet NHF's Vice President of Research Strategy, Michelle Witkop! Michelle took her passion for pain management and impactful work and joined NHF. She continues to be a vital part of the NHF community and assisting families and patients. Learn more about her role at NHF and her time working with the community!

Tell us a little bit about yourself and your role at NHF.

Pfizer and Sangamo have announced that recruitment has re-opened for the phase 3 AFFINE study for the investigational gene therapy giroctocogene fitelparvovec. This clinical study is evaluating the efficacy and safety of a single infusion of giroctocogene fitelparvovec in more than 60 adult (ages 18-64 years) participants with moderately severe to severe hemophilia A.

FOR IMMEDIATE RELEASE                                                                                

Ilana Ostrin    

Senior Director of Public Relations and Communications   

iostrin@hemophilia.org  

212-328-3769  

 

Upcoming topics include emerging research, key political issues, and more.

 

PO Box 147
Richwood, OH 43344

© Central Ohio Chapter of the National Hemophilia Foundation 2022

Crafted by Firespring